According to the research report titled ‘Global Chemotherapy Drugs Market: Analysis By Drug Type, By Administration, By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023)’, available with Market Study Report, global chemotherapy drugs market is expected to grow with a CAGR of 11.91% during 2018-2023.
 

Global chemotherapy drugs market is classified based on drug type into plant alkaloids, antitumor antibiotics, alkylating agents, and antimetabolites. Among these, plant alkaloids and antitumor antibiotics segments are poised to witness a healthy growth over the forthcoming years, owing to effective use of these medications for treating various types of cancers such as breast, lung, ovarian, bladder, melanoma, prostate, esophageal, and other solid tumors.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1856957/
 

With respect to the administration, global chemotherapy drugs industry is divided into oral and intravenous. Based on regional overview, the market is segmented into Asia Pacific, Europe, North America and rest of the world. As per the report, North America held significant market share in 2018. Meanwhile, Asia Pacific chemotherapy drugs industry is anticipated to grow at highest pace during the forecast period. Factors such as ever-growing production of pharmaceuticals, increasing cases of cancer along with government focus on medical infrastructural developments are contributing to the market growth in Asia Pacific.
 

The study on global chemotherapy drugs market highlights the trends, key drivers, existing restrains and lucrative opportunities while presenting thorough assessment of the business space. It further offers information regarding the leading players, their product portfolios along with industry share.
 

Key players operating in global chemotherapy drugs market are Teva Pharmaceutical Industries Limited, Bristol-Myers Squibb, Eli Lilly & Company, Pfizer, Celgene Corporation, GlaxoSmithKline plc, Merck & Co. Inc., Novartis, and Sanofi.